ClinicalTrials.gg

Program

EVO756

A development code. Also written as “EVO756, Dose 1”, “EVO756, Dose 2” and “Oral EVO756 300 mg QD”.

Its studies are mostly in Migraine Disorders · Dermatitis, Atopic · Chronic Urticaria, led by Evommune.

Furthest: phase 2, since Sep 17, 20244 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Evommune41 open or runningphase 2since Sep 17, 2024Sep 17, 2024Oct 2027phase 2 · NCT07616128

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2024First study: phase 2 study in Chronic Inducible UrticariaFirst studyNCT06603220 · 30 enrolled · United States
  2. Mar 7, 2025Phase 2 study in Chronic UrticariaNCT06873516 · 182 enrolled · United States, Canada, Japan
  3. Aug 28, 2025Phase 2 study in Dermatitis, AtopicNCT07150845 · 121 enrolled · United States, New Zealand
  4. May 19, 2026Phase 2 study in Migraine DisordersNCT07616128 · 330 planned · United States, Australia, Canada and more

Ahead

  1. Oct 2027Primary completion: phase 2 study in Migraine DisordersNCT07616128

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07616128Migraine Disorders · United States, Australia, Canada and more2RecruitingOct 2027330
NCT07150845Dermatitis, Atopic · United States, New Zealand2CompletedJul 23, 2026121
NCT06873516Chronic Urticaria · United States, Canada, Japan2CompletedMay 29, 2026182
NCT06603220Chronic Inducible Urticaria · United States2CompletedMay 8, 202530

How it is read

Names in the registry

  • “EVO756”, 6 entries
  • “EVO756, Dose 1”, 1 entry
  • “EVO756, Dose 2”, 1 entry
  • “Oral EVO756 300 mg QD”, 1 entry
  • “Oral EVO756 50 mg BID”, 1 entry

Codes read as this program: EVO756.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.